{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:48:21Z","timestamp":1792756101085,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004769","name":"Universit\u00e0 degli Studi di Pavia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s12325-021-01728-4","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T19:03:07Z","timestamp":1623265387000},"page":"3986-3996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod"],"prefix":"10.1007","volume":"38","author":[{"given":"Lucilla","family":"Barbano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ziccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriana","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Gabri","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Mataluni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Falsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolama Alessandra","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"1728_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"1728_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med"},{"key":"1728_CR3","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","volume":"84","author":"L Kappos","year":"2015","unstructured":"Kappos L, O\u2019Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84:1582\u201391.","journal-title":"Neurology"},{"key":"1728_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung H. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91\u2013101.","journal-title":"Clin Neuropharmacol"},{"key":"1728_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/eye.2016.258","volume":"31","author":"P Mandal","year":"2017","unstructured":"Mandal P, Gupta A, Fusi-Rubiano W, Keane PA, Yang Y. Fingolimod: therapeutic mechanisms and ocular adverse effects. Eye (Lond). 2017;31:232\u201340.","journal-title":"Eye (Lond)"},{"key":"1728_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.semcdb.2004.05.002","volume":"15","author":"T Hla","year":"2004","unstructured":"Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol. 2004;15:513\u201320.","journal-title":"Semin Cell Dev Biol"},{"key":"1728_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"BZ Chaudhry","year":"2017","unstructured":"Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14:859\u201373.","journal-title":"Neurotherapeutics"},{"key":"1728_CR8","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1097\/IOP.0000000000000774","volume":"33","author":"KL Christopher","year":"2017","unstructured":"Christopher KL, Elner VM, Demirci H. Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis. Ophthal Plast Reconstr Surg. 2017;33:e73\u20135.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"1728_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/WNO.0b013e31829b42e1","volume":"33","author":"MT Bhatti","year":"2013","unstructured":"Bhatti MT, Freedman SM, Mahmoud TH. Fingolimod therapy and macular hemorrhage. J Neuroophthalmol. 2013;33:370\u20132.","journal-title":"J Neuroophthalmol"},{"key":"1728_CR10","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1097\/IAE.0000000000002334","volume":"38","author":"PI Sia","year":"2018","unstructured":"Sia PI, Aujla JS, Chan WO, Simon S. Fingolimod-associated retinal hemorrhages and roth spots. Retina. 2018;38:e80\u20131.","journal-title":"Retina"},{"key":"1728_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12886-015-0125-9","volume":"15","author":"N Ueda","year":"2015","unstructured":"Ueda N, Saida K. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. BMC Ophthalmol. 2015;15:135.","journal-title":"BMC Ophthalmol"},{"key":"1728_CR12","doi-asserted-by":"publisher","first-page":"e909","DOI":"10.1212\/NXI.0000000000000909","volume":"8","author":"A Abraham","year":"2020","unstructured":"Abraham A, Nicholson L, Dick A, Rice C, Atan D. Intermediate uveitis associated with MS: diagnosis, clinical features, pathogenic mechanisms, and recommendations for management. Neurol Neuroimmunol Neuroinflamm. 2020;8:e909.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1728_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.msard.2020.102125","volume":"42","author":"LY Goh","year":"2020","unstructured":"Goh LY, Kirthi V, Silber E, Harvey JP, Jackson TL. Real-world incidence of fingolimod-associated macular oedema. Mult Scler Relat Disord. 2020;42:102\u201325.","journal-title":"Mult Scler Relat Disord"},{"key":"1728_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.msard.2015.06.015","volume":"4","author":"K Schr\u00f6der","year":"2015","unstructured":"Schr\u00f6der K, Finis D, Harmel J, et al. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. Mult Scler Relat Disord. 2015;4:406\u20138.","journal-title":"Mult Scler Relat Disord"},{"key":"1728_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12948-020-00119-4","volume":"18","author":"R Husmann","year":"2020","unstructured":"Husmann R, Davies JB, Ghannam M, Berry B, Kelkar P. Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications. Clin Mol Allergy. 2020;18:3.","journal-title":"Clin Mol Allergy"},{"key":"1728_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1352458514528759","volume":"21","author":"S Thoo","year":"2015","unstructured":"Thoo S, Cugati S, Lee A, Chen C. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Mult Scler. 2015;21:249\u201351.","journal-title":"Mult Scler"},{"key":"1728_CR17","doi-asserted-by":"publisher","first-page":"e4180","DOI":"10.1097\/MD.0000000000004180","volume":"95","author":"H Akiyama","year":"2016","unstructured":"Akiyama H, Suzuki Y, Hara D, et al. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: a case report. Medicine (Baltimore). 2016;95:e4180.","journal-title":"Medicine (Baltimore)"},{"key":"1728_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000315109","volume":"26","author":"S Lucke","year":"2010","unstructured":"Lucke S, Levkau B. Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem. 2010;26:87\u201396.","journal-title":"Cell Physiol Biochem"},{"key":"1728_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/jcb.20088","volume":"92","author":"BJ McVerry","year":"2004","unstructured":"McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem. 2004;92:1075\u201385.","journal-title":"J Cell Biochem"},{"key":"1728_CR20","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1097\/WNO.0000000000000937","volume":"41","author":"L Ziccardi","year":"2021","unstructured":"Ziccardi L, Landi D, De Geronimo D, et al. Choriocapillaris integrity in relapsed central serous chorioretinopathy in a patient treated with fingolimod for multiple sclerosis: new insights from optical coherence tomography angiography. J Neuroophthalmol. 2021;41:e51\u20133.","journal-title":"J Neuroophthalmol"},{"key":"1728_CR21","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1172\/JCI76369","volume":"125","author":"RL Proia","year":"2015","unstructured":"Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125:1379\u201387.","journal-title":"J Clin Invest"},{"key":"1728_CR22","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/bcp.12454","volume":"78","author":"M Ocwieja","year":"2014","unstructured":"Ocwieja M, Meiser K, David OJ, et al. Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers. Br J Clin Pharmacol. 2014;78:1354\u201365.","journal-title":"Br J Clin Pharmacol"},{"key":"1728_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386\u201394.","journal-title":"Ophthalmology"},{"key":"1728_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000446321","volume":"56","author":"M Dettoraki","year":"2016","unstructured":"Dettoraki M, Moschos MM. The role of multifocal electroretinography in the assessment of drug-induced retinopathy: a review of the literature. Ophthalmic Res. 2016;56:169\u201377.","journal-title":"Ophthalmic Res"},{"key":"1728_CR25","doi-asserted-by":"crossref","unstructured":"Hood DC, Bach M, Brigell M, et al. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition) Doc Ophthalmol. 2012;124:1\u201313.","DOI":"10.1007\/s10633-011-9296-8"},{"key":"1728_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1364\/JOSAA.13.000634","volume":"13","author":"MA Bearse","year":"1996","unstructured":"Bearse MA, Sutter EE. Imaging localized retinal dysfunction with the multifocal electroretinogram. J Opt Soc Am A Opt Image Sci Vis. 1996;13:634\u201340.","journal-title":"J Opt Soc Am A Opt Image Sci Vis"},{"key":"1728_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1350-9462(00)00013-6","volume":"19","author":"DC Hood","year":"2000","unstructured":"Hood DC. Assessing retinal function with the multifocal technique. Prog Retin Eye Res. 2000;19:607\u201346.","journal-title":"Prog Retin Eye Res"},{"key":"1728_CR28","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.3390\/jcm9113766","volume":"9","author":"L Ziccardi","year":"2020","unstructured":"Ziccardi L, Barbano L, Boffa L, et al. Functional assessment of outer and middle macular layers in multiple sclerosis. J Clin Med. 2020;9:3766.","journal-title":"J Clin Med"},{"key":"1728_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"1728_CR30","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1167\/iovs.07-0834","volume":"48","author":"FC Gundogan","year":"2007","unstructured":"Gundogan FC, Demirkaya S, Sobaci G. Is optical coherence tomography really a new biomarker candidate in multiple sclerosis?\u2014A structural and functional evaluation. Investig Ophthalmol Vis Sci. 2007;48:5773\u201381.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1728_CR31","first-page":"3643","volume":"41","author":"VC Greenstein","year":"2000","unstructured":"Greenstein VC, Holopigian K, Hood DC. The nature and extent of retinal dysfunction associated with diabetic macular oedema. Invest Ophthalmol Vis Sci. 2000;41:3643\u201354.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1728_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.sjopt.2010.04.005","volume":"24","author":"M Abdel-Kader","year":"2010","unstructured":"Abdel-Kader M, El-Dessouky WM. Multifocal electroretinogram in retinal vein occlusion. Saudi J Ophthalmol. 2010;24:125\u201332.","journal-title":"Saudi J Ophthalmol"},{"key":"1728_CR33","doi-asserted-by":"publisher","unstructured":"Simon MV, Basu SK, Qaladize B, Grambergs RC, Rotstein NP, Mandal N. Sphingolipids as critical players in retinal physiology and pathology. J Lipid Res. 2020:jlr.TR120000972. https:\/\/doi.org\/10.1194\/jlr.TR120000972.","DOI":"10.1194\/jlr.TR120000972"},{"key":"1728_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fncel.2019.00246","volume":"13","author":"MV Sim\u00f3n","year":"2019","unstructured":"Sim\u00f3n MV, Prado Spalm FH, Vera MS, Rotstein NP. Sphingolipids as emerging mediators in retina degeneration. Front Cell Neurosci. 2019;13:246.","journal-title":"Front Cell Neurosci"},{"key":"1728_CR35","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1167\/iovs.09-3388","volume":"50","author":"GE Miranda","year":"2009","unstructured":"Miranda GE, Abrahan CE, Politi LE, Rotstein NP. Sphingosine-1-phosphate is a key regulator of proliferation and differentiation in retina photoreceptors. Invest Ophthalmol Vis Sci. 2009;50:4416\u201328.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1728_CR36","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1167\/iovs.10-7065","volume":"52","author":"GE Miranda","year":"2011","unstructured":"Miranda GE, Abrahan CE, Agnolazza DL, Politi LE, Rotstein NP. Ceramide-1-phosphate, a new mediator of development and survival in retina photoreceptors. Invest Ophthalmol Vis Sci. 2011;52:6580\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1728_CR37","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1194\/jlr.M035048","volume":"54","author":"H Chen","year":"2013","unstructured":"Chen H, Tran JT, Eckerd A, et al. Inhibition of de novo ceramide biosynthesis by FTY720 protects rat retina from light-induced degeneration. J Lipid Res. 2013;54:1616\u201329.","journal-title":"J Lipid Res"},{"key":"1728_CR38","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1194\/jlr.M063719","volume":"57","author":"M Stiles","year":"2016","unstructured":"Stiles M, Qi H, Sun E, et al. Sphingolipid profile alters in retinal dystrophic P23H\u20131 rats and systemic FTY720 can delay retinal degeneration. J Lipid Res. 2016;57:818\u201331.","journal-title":"J Lipid Res"},{"key":"1728_CR39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1164\/rccm.200405-684OC","volume":"170","author":"BJ McVerry","year":"2004","unstructured":"McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med. 2004;170:987\u201393.","journal-title":"Am J Respir Crit Care Med"},{"key":"1728_CR40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1161\/01.RES.0000338501.84810.51","volume":"103","author":"M Tauseef","year":"2008","unstructured":"Tauseef M, Kini V, Knezevic N, et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res. 2008;103:1164\u201372.","journal-title":"Circ Res"},{"key":"1728_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/eye.2009.318","volume":"24","author":"GA Lutty","year":"2010","unstructured":"Lutty GA, Hasegawa T, Baba T, Grebe R, Bhutto I, McLeod DS. Development of the human choriocapillaris. Eye (Lond). 2010;24:408\u201315.","journal-title":"Eye (Lond)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01728-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01728-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T04:24:18Z","timestamp":1626236658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01728-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01728-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}